Can females have gynaecomastia? In the strict clinical sense, no — gynaecomastia is defined as the benign enlargement of glandular breast tissue in people assigned male at birth, caused by an oestrogen-androgen imbalance. However, females can experience a range of breast tissue changes that may feel or appear similar, including fibroadenomas, hormonal breast enlargement, and medication-related effects. Understanding the distinction between gynaecomastia and female breast conditions is essential for accurate diagnosis and appropriate care. This article explains the evidence, common causes, and when to seek NHS advice.

What Is Gynaecomastia and Who Can It Affect?

Gynaecomastia is defined as benign glandular breast enlargement in people assigned male at birth; females cannot have gynaecomastia by clinical definition, though they can experience other breast tissue changes.

Have any more questions about this? Message our pharmaceutical team to get more info →

Gynaecomastia is a clinical term referring to the benign enlargement of glandular breast tissue in people assigned male at birth (AMAB), caused by an imbalance between oestrogen and androgen hormones. The word derives from the Greek for 'woman-like breasts', and the diagnosis is formally defined as a condition affecting those with male physiology. In this strict medical sense, females cannot have gynaecomastia, because the diagnosis is specific to the development of excess glandular tissue in people who are AMAB.

This does not mean that females are immune to abnormal or unwanted breast tissue changes. Women can experience a range of conditions that cause breast enlargement, lumpiness, tenderness, or asymmetry — some of which may superficially resemble what is described in gynaecomastia. Understanding the distinction is important, both for accurate diagnosis and for ensuring patients receive the most appropriate care.

For transgender women (assigned male at birth) undergoing feminising hormone therapy, breast development is an expected and intended effect of treatment rather than a pathological process, and is not typically classified as gynaecomastia. For transgender men or non-binary individuals assigned female at birth, breast tissue changes related to hormone therapy fall outside the traditional gynaecomastia definition but still warrant clinical attention if unexpected or concerning. People with differences of sex development (DSD/intersex variations) may also present with breast changes that require individual clinical assessment. In all cases, any new or unexplained breast change should be assessed by a qualified healthcare professional. Further information on gynaecomastia in those assigned male at birth is available from the NHS and NICE Clinical Knowledge Summary (CKS) on Gynaecomastia.

Breast Tissue Changes in Females: What the Evidence Shows

Females commonly experience benign breast changes — including fibroadenomas, cysts, and mastalgia — driven by hormonal fluctuations; these are distinct from gynaecomastia but warrant clinical assessment if new or unexplained.

In females, the breast is composed of glandular tissue, adipose (fatty) tissue, and connective tissue, all of which are hormonally sensitive. Throughout a woman's life, breast tissue naturally changes in response to the menstrual cycle, pregnancy, breastfeeding, and the menopause. These physiological changes are entirely normal and do not represent a pathological process.

That said, abnormal breast tissue growth in women is well-documented and can arise from a variety of hormonal, pharmacological, and structural causes. Conditions such as fibroadenoma, benign breast changes (including cyclical breast pain, mastalgia, and cysts — sometimes referred to in older literature as fibrocystic change), and increased adipose tissue in the breast (macromastia) are among the most common benign findings. These are distinct from gynaecomastia but can cause similar symptoms, including:

• Noticeable breast enlargement or asymmetry

• A firm or rubbery lump, which in the case of fibroadenoma may occur anywhere in the breast (particularly in younger women)

• Breast tenderness or discomfort

• Changes in breast shape or texture

Research consistently shows that hormonal fluctuations — particularly involving oestrogen, progesterone, and prolactin — play a central role in driving these changes. The NHS advises that most breast changes in women are benign, but emphasises that any new lump, skin change, nipple discharge (particularly unilateral, spontaneous, or blood-stained discharge), or skin changes such as peau d'orange (orange-peel skin texture) should be evaluated promptly to rule out more serious pathology, including breast cancer. Early assessment remains the cornerstone of safe breast health management. Further guidance is available from the NHS on breast lumps and breast cancer symptoms, and from NICE CKS on breast lumps in women.

Common Causes of Abnormal Breast Tissue Growth in Women

Hormonal imbalances (e.g., PCOS, hyperprolactinaemia), certain medicines (e.g., antipsychotics, HRT, spironolactone), and obesity are the most common causes of abnormal breast tissue growth in women.

Several well-established factors can contribute to abnormal breast tissue growth in women. Understanding these causes helps contextualise why some women may experience changes that feel similar to those described in gynaecomastia, even though the underlying mechanisms differ.

Hormonal imbalances are among the most frequent drivers. Conditions such as polycystic ovary syndrome (PCOS), hyperprolactinaemia (elevated prolactin levels, which may be caused by a prolactinoma), and hypothyroidism can all disrupt the hormonal environment of the breast, leading to enlargement or tenderness. Similarly, the natural hormonal shifts of puberty, pregnancy, and the perimenopause can cause temporary or lasting breast changes. In rare cases, a condition called gigantomastia — extreme breast enlargement — may occur, particularly during pregnancy or in association with certain medications.

Medications are another important consideration. Certain drugs are known to influence breast tissue in women, and their Summary of Product Characteristics (SmPC) or British National Formulary (BNF) entries list breast-related effects such as mastalgia, galactorrhoea, or breast enlargement as recognised adverse effects. Examples include:

• Antipsychotics (e.g., haloperidol, risperidone) — which raise prolactin levels and may cause galactorrhoea or breast tenderness

• Hormonal contraceptives — oestrogen-containing preparations may increase breast fullness or tenderness

• Hormone replacement therapy (HRT) — particularly combined oestrogen-progestogen regimens

• Spironolactone — an aldosterone antagonist with anti-androgenic properties

• Metoclopramide — a dopamine antagonist that raises prolactin levels

• Some SSRIs and antidepressants — which may have indirect hormonal effects

• Cimetidine — an H2-receptor antagonist with weak anti-androgenic activity

The extent and nature of breast effects vary considerably between individuals and between specific medicines; the SmPC or BNF entry for each medicine provides the most accurate and up-to-date information. If you are concerned that a prescribed medicine may be affecting your breast tissue, do not stop taking it without first consulting your prescriber. If you suspect a medicine is causing a side effect, you can report this via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Obesity can also contribute, as adipose tissue produces oestrogen peripherally, potentially stimulating breast tissue growth. Additionally, benign structural causes — such as fibroadenomas, cysts, or lipomas — may present as discrete lumps rather than generalised enlargement. In rare cases, breast enlargement may signal an underlying endocrine tumour or, critically, breast cancer, which is why clinical evaluation is always recommended.

When to Seek Medical Advice and What to Expect on the NHS

Women should contact their GP promptly for any new breast lump, skin change, nipple discharge, or unexplained pain; NICE NG12 supports urgent two-week wait referral for women aged 30 and over with an unexplained lump.

Women should contact their GP promptly if they notice any of the following changes in their breasts:

• A new lump or thickening, particularly if it feels hard or is fixed in place

• Unexplained changes in breast size or shape

• Skin changes such as dimpling, puckering, redness, or peau d'orange (skin resembling orange peel)

• Nipple changes, including inversion, unilateral spontaneous or blood-stained discharge, or crusting

• Persistent breast pain that is new or unexplained

Whilst the majority of breast changes in women are benign, the NHS recommends that any new or unusual finding be assessed without delay. GPs will typically take a thorough history, including details of the menstrual cycle, current medications, family history of breast disease, and any relevant systemic symptoms. A physical examination of both breasts, axillae (armpits), and regional lymph nodes will usually follow.

In line with NICE guideline NG12 (Suspected Cancer: Recognition and Referral), GPs should consider an urgent two-week wait (2WW) referral to a specialist breast clinic in the following circumstances:

• Women aged 30 and over with an unexplained breast lump, with or without pain

• Women under 30 with an unexplained breast lump (consider urgent referral)

• Women of any age with skin changes suggestive of breast cancer

• Women aged 50 and over with unilateral nipple discharge, retraction, or other nipple changes

This referral does not necessarily mean cancer is suspected — it is a precautionary measure to ensure timely and thorough assessment within 14 days. Patients should feel reassured that seeking advice early is always the right course of action, and that the NHS breast service is well-equipped to investigate and manage a wide range of breast conditions. Further information is available from the NHS on breast lumps and breast cancer symptoms, and from NICE NG12.

Diagnosis and Treatment Options Available in the UK

UK breast clinics use triple assessment — clinical examination, imaging, and core needle biopsy — to diagnose breast conditions; treatment depends on the underlying cause and ranges from reassurance to surgery.

When a woman is referred to a breast clinic, the diagnostic process typically follows a structured approach known as triple assessment, as set out in the Association of Breast Surgery (ABS) Best Practice Diagnostic Guidelines and supported by Royal College of Radiologists (RCR) breast imaging guidance. Triple assessment combines:

1. Clinical examination — a thorough physical assessment by a specialist
2. Imaging — typically ultrasound in younger women (under 40) or mammography in older women, or both, depending on clinical findings; the choice of modality follows UK symptomatic breast clinic protocols
3. Pathological sampling — a core needle biopsy is the standard method for obtaining tissue diagnosis in UK practice; fine needle aspiration (FNA) now has a limited role, primarily for cyst aspiration or lymph node assessment

This approach ensures that benign and malignant conditions are accurately distinguished. Most women will receive a benign diagnosis, and in many cases, no specific treatment is required beyond reassurance and monitoring.

For conditions with an identifiable cause, treatment is directed accordingly:

• Hormonal imbalances may be managed with medication adjustments or endocrine treatment under specialist supervision

• Medication-induced breast changes may resolve after reviewing or switching the causative drug, in consultation with the prescribing clinician — do not stop or alter prescribed medicines without medical advice

• Fibroadenomas are often managed conservatively, though surgical excision is available if the lump is large, growing, or causing significant distress

• Benign breast pain (mastalgia) should be managed in line with NICE CKS guidance: reassurance and a well-fitting supportive bra are first-line measures, alongside topical NSAIDs (e.g., topical diclofenac) for localised pain; hormonal agents such as danazol or tamoxifen are reserved for specialist use in refractory cases and are not routinely recommended in primary care

Surgical options, including reduction mammoplasty, are available on the NHS in specific circumstances where breast enlargement causes significant physical or psychological impact, though access may vary by Integrated Care Board (ICB). Private surgical options are also available for those who wish to pursue them independently.

Living With Breast Tissue Changes: Support and Next Steps

Women experiencing breast changes can access support from Breast Cancer Now, Macmillan, and the NHS website; managing any underlying hormonal condition is often the most effective long-term strategy.

Experiencing unexpected changes in breast tissue can be distressing, regardless of the underlying cause. It is entirely natural to feel anxious whilst awaiting investigation or diagnosis, and patients should be encouraged to seek both clinical and emotional support throughout the process.

Several reputable UK organisations offer information and support for people affected by breast conditions:

• Breast Cancer Now (breastcancernow.org) — provides evidence-based information and a helpline staffed by specialist nurses

• Breast Cancer UK — focuses on prevention and awareness

• Macmillan Cancer Support (macmillan.org.uk) — offers broader support for anyone referred to a breast clinic or diagnosed with cancer

• The NHS website (nhs.uk) — offers clear, accessible guidance on breast health, symptoms, breast awareness, and when to seek help

For women whose breast changes are linked to hormonal conditions such as PCOS, prolactinoma, or thyroid disease, managing the underlying condition is often the most effective long-term strategy. Regular follow-up with a GP or specialist, alongside any recommended lifestyle modifications — such as maintaining a healthy weight and limiting alcohol intake — can help reduce the risk of recurrence or progression.

If you are taking a medicine that you think may be affecting your breast tissue, do not stop it without speaking to your prescriber first. Suspected side effects from any medicine can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Whilst females cannot technically have gynaecomastia in the clinical sense, the breast tissue changes they experience are no less valid or worthy of medical attention. Any woman who is concerned about her breast health should feel empowered to speak to her GP without delay. Early assessment, accurate diagnosis, and appropriate support are the foundations of good breast health — and the NHS is well-placed to provide all three.

Frequently Asked Questions